Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium
19 November 2021 - 1:00AM
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage
biopharmaceutical company developing disruptive therapeutics for
the treatment of patients with cancer today announced that an
abstract for SBP-101, a proprietary polyamine analogue, has been
accepted for poster presentation at the American Society of
Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which
will be held January 20-22, 2022.
Details of the presentation are as follows:
Poster Presentation
- Title: Efficacy of
SBP-101, a polyamine metabolic inhibitor, administered in
combination with gemcitabine and nab-paclitaxel, as a first-line
treatment for patients with metastatic pancreatic ductal
adenocarcinoma.
- Session Name:
Poster Session B: Pancreas, Small Bowel, and Hepatobiliary
Tract
Additional meeting information can be found on the ASCO
website https://meetings.asco.org/gi/. The full
abstract will be made available online via
https://meetinglibrary.asco.org at 5:00 PM (EST) on January 18,
2022.
About SBP-101SBP-101 is a proprietary polyamine
analogue designed to induce polyamine metabolic inhibition (PMI) by
exploiting an observed high affinity of the compound for pancreatic
ductal adenocarcinoma and other tumors. The molecule has shown
signals of tumor growth inhibition in clinical studies of US and
Australian metastatic pancreatic cancer patients, suggesting
potential complementary activity with an existing FDA-approved
standard chemotherapy regimen. In data evaluated from clinical
studies to date, SBP-101 has not shown exacerbation of bone marrow
suppression and peripheral neuropathy, which can be
chemotherapy-related adverse events. Serious visual adverse events
have been evaluated and patients with a history of retinopathy or
at risk of retinal detachment will be excluded from future SBP-101
studies. The safety data and PMI profile observed in the current
Panbela sponsored clinical trial provides support for continued
evaluation of SBP-101 in a randomized clinical trial. For more
information, please
visit https://clinicaltrials.gov/ct2/show/NCT03412799 .
About PanbelaPanbela Therapeutics, Inc. is a
clinical-stage biopharmaceutical company developing disruptive
therapeutics for patients with urgent unmet medical needs. The
company’s initial product candidate, SBP-101, is for the treatment
of patients with metastatic pancreatic ductal adenocarcinoma, the
most common type of pancreatic cancer. Panbela Therapeutics, Inc.
is dedicated to treating patients with pancreatic cancer and
exploring SBP-101’s potential for efficacy in combination with
other agents in other cancer indications. Further information can
be found
at www.panbela.com. Panbela
Therapeutics, Inc. common stock is listed on The Nasdaq Stock
Market LLC under the symbol PBLA.
Cautionary Statement Regarding Forward-Looking
StatementsThis press release contains “forward-looking
statements,” including within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: “believe,” “expect,” “intend,” “may,”
and “plan.” Examples of forward-looking statements include
statements we make regarding our intention to continue to innovate
and build our patent portfolio. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations,
and assumptions regarding the future of our business, future plans
and strategies, projections, anticipated events and trends, the
economy and other future conditions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside of our control.
Our actual results and financial condition may differ materially
and adversely from the forward-looking statements. Therefore, you
should not rely on any of these forward-looking statements.
Important factors that could cause our actual results and financial
condition to differ materially from those indicated in the
forward-looking statements include, among others, the following:
(i) our ability to obtain additional funding to complete a
randomized clinical trial; (ii) progress and success of our Phase 1
clinical trial; (iii) the impact of the current COVID-19 pandemic
on our ability to complete monitoring and reporting in our current
clinical trial and procure the active ingredient; (iv) our ability
to demonstrate the safety and effectiveness of our SBP-101 product
candidate (v) our ability to obtain regulatory approvals for our
SBP-101 product candidate in the United States, the European Union
or other international markets; (vi) the market acceptance and
level of future sales of our SBP-101 product candidate; (vii) the
cost and delays in product development that may result from changes
in regulatory oversight applicable to our SBP-101 product
candidate; (viii) the rate of progress in establishing
reimbursement arrangements with third-party payors; (ix) the effect
of competing technological and market developments; (x) the costs
involved in filing and prosecuting patent applications and
enforcing or defending patent claims; and (xi) such other factors
as discussed in Part I, Item 1A under the caption “Risk Factors” in
our most recent Annual Report on Form 10-K, any additional risks
presented in our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K. Any forward-looking statement made by us in
this press release is based on information currently available to
us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement or
reasons why actual results would differ from those anticipated in
any such forward-looking statement, whether written or oral,
whether as a result of new information, future developments or
otherwise.
Contact Information:
Investors:James CarbonaraHayden IR(646)
755-7412james@haydenir.com
Media:Tammy GroenePanbela Therapeutics, Inc.(952) 479-1196 ext.
170IR@panbela.com
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Apr 2024 to May 2024
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From May 2023 to May 2024